ABSTRACT
The aim of study was to evaluate a drug sensitivity of M. avium-intracellulare, M. xenopi and M. kansasii cultured from 55 patients with mycobacterioses. The identification of strains was performed with morphological and biochemical tests and thin-layer chromatography. Resistance tests were done on egg L-J and agar media for selected drugs. It was documented that MAIC strains were non-sensitive on isoniazid and rifampicin, and other ones. The most active drug was cycloserine inhibiting growth of 80% but rifabutine--50% of strains. M. xenopi strains were sensitive for tested drugs including isoniazid and rifampicin (about 30%). M. kansasii strains were in 100% sensitive for cyclosporine, rifabutine, Davercin and ofloxacin and partly for isoniazid, streptomycin and Augmentin.
Subject(s)
Mycobacterium avium Complex/drug effects , Mycobacterium avium-intracellulare Infection/microbiology , Female , Humans , Male , Microbial Sensitivity Tests , Mycobacterium Infections, Nontuberculous/drug therapy , Mycobacterium avium-intracellulare Infection/drug therapy , Species SpecificityABSTRACT
Sensitivity of cephaperasone (CEFOBID) of 966 straits of microorganisms, isolated from 661 patients was assessed. The study was carried out according to the trial described by Bauer et al, using the Mueller-Hinton medium and original cephaperasone tests (Pfizer). Full sensitivity was found in 87.1% of the organisms. The following conclusions were made: 1. Most isolated organisms were sensitivite to cephaperasone (87.1%); E. coli (98.5%), Kl. Pneumoniae (94.8%), Atrobacter (93.1%), Enterobacter (92.8%), Klebsiella sp (92.5%). Lowered sensitivity was seen in Pseudomonas sp. (70.9%), Acinobacter (70.8%) and Alcaligenes (58.3%). 2. Cross-resistance with other cephalosporines was found in 27.8% of the cases. In 52.4% full sensitivity to cephaperasone was found, and resistance to other clinically used cephalosporines.
Subject(s)
Cefoperazone/pharmacology , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae/drug effects , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/drug effects , Respiratory Tract Infections/microbiology , Sputum/microbiology , Adult , Aged , Drug Evaluation, Preclinical , Drug Resistance, Microbial , Female , Humans , In Vitro Techniques , Male , Middle AgedABSTRACT
2-Amino-3-chloropyrazine and 2-amino-6-chloropyrazine were reacted with appropriate sodium alkoxides to give 2-aminopyrazine derivatives with the methoxy, benzyloxy, chlorobenzyloxy, dichlorobenzyloxy, bromobenzyloxy or dibromobenzyloxy group at positions 3 and 6 (I-XIV). The obtained compounds were converted into N-pyrazinyl-N'-benzoylthioureas (XV-XXXI) by reacting with benzoyl isothiocyanate. Their hydrolysis yielded N-pyrazinylthioureas XXXII-XLVII. Analogical reactions of alkoxyaminopyrazines with p-chlorophenyl isothiocyanate or 2,6-dichlorophenyl isothiocyanate afforded corresponding N-pyrazinyl-N'-(p-chlorophenyl)thioureas and N-pyrazinyl-N'- (2,6-dichlorophenyl)thioureas (XLVIII-LVIII). The obtained compounds were found to display tuberculostatic in vitro activity with MIC values from 8 meg/cm3 to 1000 mu meg/cm3.